sacubitril / valsartan

Known as: SACUBITRIL/VALSARTAN, sacubitril-valsartan, valsartan and sacubitril 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Sacubitril/Valsartan, proved superiority over other conventional heart failure management treatments, but its mechanisms of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2017
2017
BACKGROUND Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • table 4
Is this relevant?
2016
2016
AIMS To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
AIMS In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2016
2016
BACKGROUND Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in… (More)
  • figure 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Is this relevant?
2016
2016
BACKGROUND Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2016
2016
BACKGROUND The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
IMPORTANCE The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
AIMS Concomitant renin-angiotensin-aldosterone system blockade and natriuretic peptide system enhancement may provide unique… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
1. Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) providing simultaneous inhibition of… (More)
Is this relevant?